Have a personal or library account? Click to login
Therapeutic drug monitoring of atypical antipsychotic drugs Cover

Therapeutic drug monitoring of atypical antipsychotic drugs

Acta Pharmaceutica
Volume 64 (2014): Issue 4 (December 2014)
By: Milan Grundmann,  Ivana Kacirova and  Romana Urinovska  
Open Access
|Dec 2014

References

  1. 1. M. Grundmann and I. Kacirova, Significance of TDM, phenotyping and genotyping for the correct drug dosage, Cas. Lek. Ces. 149 (2010) 482-487.
    Search in Google Scholar
  2. 2. M. Grundmann, I. Kacirova and R. Urinovska, Therapeutic monitoring of psychoactive drugs - antidepressants: A review, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. (2013) in press; DOI: 10.5507/bp.2013.020.10.5507/bp.2013.02023549513
    Search in Google Scholar
  3. 3. I. Kacirova, M. Grundmann and R. Urinovska, General principles of therapeutic monitoring of psychoactive drugs, Klin. Farmakol. Farm. 26 (2012) 131-134.
    Search in Google Scholar
  4. 4. C. Hiemke and M. Shams, Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry, Curr. Drug Del. 10 (2013) 46-53.10.2174/156720181131001000822998042
    Search in Google Scholar
  5. 5. M. R. Muscatello, A. Bruno, G. Pandolfo, U. Micò, S. Settineri and R. Zoccali, Emerging treatments in the management of schizophrenia - focus on sertindole, Drug Des. Devel. Ther. 4 (2010) 187-201; DOI: 10.2147/DDDT.S6591.10.2147/DDDT.S6591293976320856845
    Search in Google Scholar
  6. 6. J. M. Kane and C. U. Correll, Past and present progress in the pharmacologic treatment of schizophrenia, J. Clin. Psychiatry 71 (2010) 1115-1124; DOI: 10.4088/JCP.10r06264yel10.4088/JCP.10r06264yel306524020923620
    Search in Google Scholar
  7. 7. J. W. Newcomer, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs 19 (Suppl. 1) (2005) 1-93.
    Search in Google Scholar
  8. 8. N. Herrmann and K. L. Lanctot, Do atypical antipsychotics cause stroke?, CNS Drugs 19 (2005) 91-103.10.2165/00023210-200519020-0000115697324
    Search in Google Scholar
  9. 9. B. Luft and D. Taylor, A review of atypical antipsychotic drugs versus conventional medication in schizophrenia, Expert Opin. Pharmacother. 7 (2006) 1739-1748.10.1517/14656566.7.13.173916925501
    Search in Google Scholar
  10. 10. J. C. Huffman and J. E. Alpert, An approach to the psychopharmacologic care of patients: antidepressants, antipsychotics, anxiolytics, mood stabilizers, and natural remedies, Med. Clin. North Am. 94 (2010) 1141-1160; DOI: 10.1016/j.mcna.2010.08.009.10.1016/j.mcna.2010.08.00920951275
    Search in Google Scholar
  11. 11. C. Hiemke, A. Dragicevic, G. Gründer, S. Hättter, J. Sachse, I. Vernaleken and M. J. Müller, Therapeutic monitoring of new antipsychotic drugs, Ther. Drug Monit. 26 (2004) 156-160.10.1097/00007691-200404000-0001215228157
    Search in Google Scholar
  12. 12. L. Farde, A. L. Nordström, F. A. Wiesel, S. Pauli, C. Halldin and G. Sedvall, Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects, Arch. Gen. Psychiatry 49 (1992) 538-544.10.1001/archpsyc.1992.018200700320051352677
    Search in Google Scholar
  13. 13. S. Nyberg, A. L. Nordström, C. Halldin and L. Farde, Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man, Int. Clin. Psychopharmacol. 10 (Suppl. 3) (1995) 81-85.10.1097/00004850-199509000-00011
    Search in Google Scholar
  14. 14. P. J. Perry, Therapeutic drug monitoring of atypical antipsychotics. Is it of potential clinical value? CNS Drugs 13 (2000) 167-171.
    Search in Google Scholar
  15. 15. M. C. Mauri, L. S. Volonteri, A. Colasanti, A. Fiorentini, I. F. de Gaspari and S. R. Bareggi, Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response, Clin. Phamacokinet. 46 (2007) 359-388.10.2165/00003088-200746050-0000117465637
    Search in Google Scholar
  16. 16. L. Urichuk, T. I. Prior, S. Dursun and G. Baker, Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions, Curr. Drug Metab. 9 (2008) 410-418.
    Search in Google Scholar
  17. 17. E. Spina and J. de Leon, Metabolic drug interactions with newer antipsychotics: A comparative review, Basic Clin. Pharmacol. 100 (2007) 4-22.10.1111/j.1742-7843.2007.00017.x17214606
    Search in Google Scholar
  18. 18. R. C. Dorey, S. H. Preskorn and P. K. Widener, Results compared for tricyclic antidepressants as assayed by liquid chromatography and enzyme immunoassay, Clin. Chem. 34 (1988) 2348-2351.10.1093/clinchem/34.11.2348
    Search in Google Scholar
  19. 19. F. Saint-Marcoux, F. L. Sauvage and P. Marquet, Current role of LC-MS in therapeutic drug monitoring, Anal. Bioanal. Chem. 388 (2007) 1327-1349.10.1007/s00216-007-1320-117520242
    Search in Google Scholar
  20. 20. D. J. Brunswick, B. Needelman and J. Mendels, Specific radioimmunoassay of amitriptyline and nortriptyline, J. Clin. Pharmacol. 7 (1979) 343-348.10.1111/j.1365-2125.1979.tb00943.x1429641444353
    Search in Google Scholar
  21. 21. C. Fernandes, E. Hoeck, P. Sandra and F. M. Lancas, Determination of fluoxetine in plasma by gas chromatography-mass spectrometry using stir bar sorptive extraction, Anal. Chim. Acta 614 (2008) 201-207; DOI: 10.1016/j.aca.2008.03.036.10.1016/j.aca.2008.03.03618420052
    Search in Google Scholar
  22. 22. C. B. Eap, G. Bouchoux, M. Amey, N. Cochard, L. Savary and P. Baumann, Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry, J. Chromatogr. Sci. 36 (1998) 365-371.10.1093/chromsci/36.7.3659679303
    Search in Google Scholar
  23. 23. R. Urinovska, H. Brozmanova, P. Sistik, P. Silhan, I. Kacirova, K. Lemr and M. Grundmann, Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum, J. Chromatogr. B. 907 (2012) 101-107; DOI: 10.1016/j.jchromb.2012.09.009.10.1016/j.jchromb.2012.09.00923026228
    Search in Google Scholar
  24. 24. H. Kirchherr and W. N. Kühn-Velten, Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, singlesample approach, J. Chromatogr. B. 843 (2006) 100-113.
    Search in Google Scholar
  25. 25. K. K. Erickson-Ridout, D. Sun and P. Lazarus, Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms, Pharmacogen. Gen. 22 (2012) 561-576; DOI: 10.1097/FPC.0b013e328354026b.10.1097/FPC.0b013e328354026b627893522565219
    Search in Google Scholar
  26. 26. J. Leon, Glucuronidation enzymes, genes and psychiatry, Int. J. Neuropsychoph. 6 (2003) 57-72.10.1017/S146114570300324912899737
    Search in Google Scholar
  27. 27. H. L. Liston, J. S. Markowitz and C. L. de Vane, Drug glucuronidation in clinical psychopharmacology, J. Clin. Psychopharmacol. 21 (2001) 500-515.10.1097/00004714-200110000-0000811593076
    Search in Google Scholar
  28. 28. A. Y. Khan and S. H. Preskorn, Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring, J. Psychiatr. Pract. 11 (2005) 289-301.
    Search in Google Scholar
  29. 29. E. Spina, A. Avenoso, G. Facciolà, M.G. Scordo, M Ancione, A. G. Madia, A. Ventimiglia and E. Perucca, Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics, Psychopharmacology 148 (2000) 83-89.10.1007/s00213005002810663421
    Search in Google Scholar
  30. 30. P. J. Perry, D. D. Miller, S. V. Arndt and R. J. Cadoret, Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients, Am. J. Psychiatry 148 (1991) 231-235.10.1176/ajp.148.10.1406-b
    Search in Google Scholar
  31. 31. O. V. Olesen, K. Thomsen, P. N. Jensen, C. Wulff, N. A. Rasmussen, C. Refshammer, J. Sørensen, M. Bysted, J. Christensen and R. Rosenberg, Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study, Psychopharmacology 117 (1995) 371-378.
    Search in Google Scholar
  32. 32. D. J. Freeman and L. K. Oyewumi, Will routine therapeutic drug monitoring have a place in clozapine therapy?, Clin. Pharmacokinet. 32 (1997) 93-100.10.2165/00003088-199732020-000019068925
    Search in Google Scholar
  33. 33. S. K. Lin, S. F. Su and C. Pan, Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms, Ther. Drug Monit. 28 (2006) 303-307.10.1097/01.ftd.0000211801.66569.8016778711
    Search in Google Scholar
  34. 34. M. van der Molen-Eijgenraam, J. T. Blanken-Meijs, M. Heeringa and A. C. van Grootheest, Delirium due to increase in clozapine level during an inflammatory reaction, Ned. Tijdschr. Geneeskd. 145 (2001) 427-430.
    Search in Google Scholar
  35. 35. J. A. Carrillo, A. G. Herraiz, S. I. Ramos and J. Benítez, Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients, J. Clin. Psychopharmacol. 18 (1998) 311-316.10.1097/00004714-199808000-000119690697
    Search in Google Scholar
  36. 36. V. Ozdemir, W. Kalow, P. Posner, E. J. Collins, J. L. Kennedy, B. K. Tang, L. J. Albers, C. Reist, R. Roy, W. Walkes and P. Afra, CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia, J. Clin. Psychopharmacol. 21 (2001) 398-407.10.1097/00004714-200108000-0000711476124
    Search in Google Scholar
  37. 37. C. Hiemke, P. Baumann, N. Bergemann, A. Conca, O. Dietmaier, K. Egberts, M. Fric, M. Gerlach, C. Greiner, G. Gründer, E. Haen, U. Havemann-Reinecke, E. Jaquenoud Sirot, H. Kirchherr, G. Laux, U. C. Lutz , T. Messer, M. J. Müller, B. Pfuhlmann, B. Rambeck, P. Riederer, B. Schoppek, J. Stingl, M. Uhr, S. Ulrich, R. Waschgler and G. Zernig, AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011, Pharmacopsychiatry 44 (2011) 195-235; DOI: 10.1055/s-0031-1286287.10.1055/s-0031-128628721969060
    Search in Google Scholar
  38. 38. E. Ceskova, Would therapeutic drug monitoring improve adherence and efficaccy of treatment in schizophrenia?, Psychiat. Prax. 12 (2011) 166-178.
    Search in Google Scholar
  39. 39. K. Seto, J. Dumontet and M. H. Ensom, Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?, Ther. Drug Monit. 33 (2011) 275-283; DOI: 10.1097/FTD.0b013e3182126d83.10.1097/FTD.0b013e3182126d8321436762
    Search in Google Scholar
  40. 40. E. Spina, A. Avenoso, G. Facciolà, M. Salemi, M. G. Scordo, M. Ancione, A. G. Madia and E. Perucca, Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia, Psychopharmacology 153 (2001) 238-243. 10.1007/s00213000057611205425
    Search in Google Scholar
  41. 41. J. K. Darby, D. J. Pasta, M. G. Wilson and J. Herbert, Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, twogroup, naturalistic study, Clin. Drug Invest. 28 (2008) 553-564.10.2165/00044011-200828090-0000218666802
    Search in Google Scholar
  42. 42. L. Citrome, Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, Expert Opin. Drug Metab. Toxicol. 8 (2012) 873-888; DOI: 10.1517/17425255.2012.693160.10.1517/17425255.2012.69316022632481
    Search in Google Scholar
  43. 43. P. G. Janicak and E. A. Winans, Paliperidone ER: a review of the clinical trial data, Neuropsychiatr. Dis. Treat. 3 (2007) 869-897.10.2147/NDT.S1365
    Search in Google Scholar
  44. 44. K. K. Erickson-Ridout, J. Zhu and P. Lazarus, Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants, Pharmacogenet. Genomics 21 (2011) 539-551; DOI: 10.1097/ FPC.0b013e328348c76b.10.1097/FPC.0b013e328348c76b628139421750471
    Search in Google Scholar
  45. 45. G. Gründer, C. Hiemke, M. Paulzen, T. Veselinovic and I. Vernaleken, Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging, Pharmacopsychiatry 44 (2011) 236-248; DOI: 10.1055/s-0031-1286282.10.1055/s-0031-128628221959785
    Search in Google Scholar
  46. 46. O. Gefvert, M. Bergström, B. Långström, T. Lundberg, L. Lindström and R. Yates, Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentration after discontinuation of quetiapine (Seroquet) in patients with schizophrenia, Psychopharmacology 135 (1998) 119-126.10.1007/s0021300504929497016
    Search in Google Scholar
  47. 47. M. C. Mauri, A. Fiorentini and L. S. Volonteri, Quetiapine in acute psychosis and personality disorders during hospitalization: assessment of a therapeutic range, Eur. Neuropsychopharmacol. 14 (2004) 283-284.
    Search in Google Scholar
  48. 48. J. R. Fabre, L. Arvanitis, J. Pultz, V. M. Jones, J. B. Malick and V. B. Slotnick, ICI 204.636. a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia, Clin. Ther. 17 (1995) 366-378.
    Search in Google Scholar
  49. 49. J. G. Small, S. R. M. Hirsch, L. A. Arvanitis, B. G. Miller and C. G. Link, Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo, Arch. Gen. Psych. 54 (1997) 549-557.
    Search in Google Scholar
  50. 50. A. Sparshatt, D. Taylor, M. X. Patel and S. Kapur, Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring, Acta Psychiatr. Scand. 120 (2009) 416-428; DOI: 10.1111/j.1600-0447.2009.01429.x.10.1111/j.1600-0447.2009.01429.x19573049
    Search in Google Scholar
  51. 51. M. J. Müller, B. Regenbogen, S. Härtter, F. X. Eich and C. Hiemke, Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia, J. Psychiatr. Res. 41 (2007) 673-679.10.1016/j.jpsychires.2005.10.00316324716
    Search in Google Scholar
  52. 52. F. Vogel, R. Gansmüller, T. Leiblein, O. Dietmaier, H. Wassmuth, G. Gründer and C. Hiemke, The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey, Eur. Psychiatry 24 (2009) 143-148; DOI: 10.1016/j. eurpsy.2008.09.003.
    Search in Google Scholar
  53. 53. M. D. Cherma, M. Reis, S. Hägg, J. Ahlner and F. Bengtsson, Therapeutic drug monitoring of ziprasidone in a clinical treatment setting, Ther. Drug Monit. 30 (2008) 682-688; DOI: 10.1097/ FTD.0b013e31818ac8ba.10.1097/FTD.0b013e31818ac8ba18824954
    Search in Google Scholar
  54. 54. A. Sparshatt, D. Taylor, M. X. Patel and S. Kapur, A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring, J. Clin. Psychiatry 71 (2010) 1447-1456; DOI: 10.4088/JCP.09r05060gre. 10.4088/JCP.09r05060gre20584524
    Search in Google Scholar
DOI: https://doi.org/10.2478/acph-2014-0036 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 387 - 401
Accepted on: Jul 3, 2014
Published on: Dec 20, 2014
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
therapeutic drug monitoring,
antipsychotic drugs,
therapeutic reference ranges
Related subjects:
Pharmacy,
Pharmacy, other

© 2014 Milan Grundmann, Ivana Kacirova, Romana Urinovska, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 64 (2014): Issue 4 (December 2014)Next article